Key result
Previous statin therapy before acute coronary syndrome was associated with a lower incidence of in-hospital MACE (3.0% vs 8.3%), with lack of prior statin use being an independent predictor of MACE (OR 2.8).
Why the study?
Does previous statin therapy initiated ≥1 month before PCI reduce periprocedural MI and in-hospital MACE in patients with ACS?
Population
479 consecutive patients with acute coronary syndrome who underwent percutaneous coronary intervention at a…
Comparison
Previous statin therapy initiated ≥1 month… vs Statin-naive patients with no prior statin…
Design
Cohort
Follow-up
in-hospital
Authors
Loading...
Supports statin pretreatment association in ACS; hypothesis-generating and requires randomized confirmation before practice change.
Cohort (n=479)
No
Does previous statin therapy initiated ≥1 month before PCI reduce periprocedural MI and in-hospital MACE in patients with ACS?
Odds Ratio: 2.8 (95% CI 1.1–7.2)
Absolute Event Rate: 3% vs 8.3%
p-value: p=0.038
Previous statin therapy initiated at least 1 month before PCI in ACS patients is associated with a significantly lower incidence of periprocedural MI and in-hospital MACE.
Yun et al. (2011) conducted a cohort in Acute Coronary Syndrome (ACS) undergoing Percutaneous Coronary Intervention (PCI) (n=479). Previous statin therapy (≥1 month before PCI) vs. Statin-naive was evaluated on In-hospital major adverse cardiovascular events (MACE) (OR 2.8, 95% CI 1.1-7.2, p=0.038). Previous statin therapy before acute coronary syndrome was associated with a lower incidence of in-hospital MACE (3.0% vs 8.3%), with lack of prior statin use being an independent predictor of MACE (OR 2.8).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: